A newly published retrospective study found that patients who received a combination therapy with infliximab and azathioprine early on had significantly increased linear growth compared to patients whose therapy was stepped up.
Conventionally, treatment for pediatric Crohn disease (CD) has focused on inducing remission with corticosteroids and maintaining remission with immunomodulators. Those patients who are refractory or intolerant to such a treatment approach are sometimes considered candidates for treatment with infliximab (an approach known as “step-up” therapy), but data on the use of early infliximab treatment in pediatric patients with CD have thus far been limited.
Information about growth failure in pediatric patients with CD has also been limited, though growth failure is recognized as a characteristic of the disease; proposed factors contributing to the problem are chronic undernutrition and the presence of inflammatory cytokines secreted from the intestine. Use of corticosteroids also increases the risk of growth failure.
A newly published retrospective study, appearing in Gut and Liver, sought to evaluate the impact of different treatment approaches on linear growth of pediatric patients with CD, and found that patients who received a combination therapy with infliximab and azathioprine early on had significantly increased linear growth compared to patients whose therapy was stepped up.
A total of 33 patients were included in the study; 16 had been allocated to the step-up group and 17 to the early combined immunosuppression group. Patients in the step-up group received an oral corticosteroid dose of 1 mg/kg daily for induction therapy, which was tapered over 8 weeks, and oral azathioprine and mesalazine for maintenance therapy (infliximab could be added in this group if necessary to maintain clinical remission). The early combined immunosuppression group received infliximab at infused doses of 5 mg/kg at weeks 0, 2, and 6 for induction, and every 8 weeks thereafter. Patients in this group initiated azathioprine at daily doses of 0.5 to 1 mg/kg, and doses were adjusted as required.
Z-scores for height (which measure children’s stature for age) for the 2 groups were as follows at 1, 2, and 3 years after diagnosis:
“Our study showed that an early combined immunosuppression strategy was superior to step-up strategy in improving long-term height z-scores,” write the authors, who add that “long-term restoration of linear growth was superior in the early combined immunosuppression when compared from diagnosis.” The authors conclude that early introduction of biologics at the time of diagnosis with pediatric CD should be considered in terms of improving linear growth.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.
Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition
June 2nd 2024On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars, as well as the feasibility of switching to them.
Trastuzumab-dkst Shows Promising Results in Real-World Setting for HER2+ Breast Cancer
July 9th 2024A Brazilian real-world study found trastuzumab-dkst to be an effective and safe adjuvant therapy for HER2-positive (HER2+) breast cancer, with clinical outcomes comparable to reference trastuzumab.